Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with non-segmental vitiligo.


Clinical Trial Description

According to available data, statins act through several immunological pathways, potentially reversing undesirable phenomena underlying autoimmune vitiligo pathogenesis. A study has been designed as a single-center, randomized, double-blind, placebo-controlled pilot study with the enrollment of at least 20 active non-segmental vitiligo patients presenting with vitiligous lesions on both upper and lower limbs. Clinical effects of ointments containing 1% simvastatin-acid sodium salt or 1% atorvastatin calcium salt applied on a preselected limb will be assessed in comparison with vehicle ointment applied on the opposite limb. All study participants will undergo clinical evaluation using Body Surface Area (BSA) and Vitiligo Area Scoring Index (VASI) scales at baseline, week 4, week 8 and week 12 time points. Precise assessment of skin lesions will be performed using photographic documentation obtained during each study visit and processed with NIS-Elements software. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03247400
Study type Interventional
Source Nicolaus Copernicus University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 1, 2016
Completion date April 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT04052425 - Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Phase 3
Completed NCT04057573 - Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Phase 3
Completed NCT04942860 - The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo Phase 3
Recruiting NCT06113328 - A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) Phase 2
Recruiting NCT01377077 - Punchgrafting Techniques for Vitiligo Phase 4
Completed NCT04927975 - Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Phase 2
Completed NCT04487860 - Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo Phase 2
Active, not recruiting NCT04811326 - Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation Phase 4
Terminated NCT03022019 - ReNovaCell in Non-segmental Vitiligo N/A
Not yet recruiting NCT05990309 - ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO N/A